J9349 HCPCS code: Injection, tafasitamab-cxix, 2 mg
J9349 is the HCPCS Level II code for injection, tafasitamab-cxix, 2 mg. In 2024 Medicare paid an average of $10.52 per service for J9349 across 1,215,326 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 900 per day on outpatient hospital claims. Medicare volume fell 18% from 2022 to 2024 (1,481,832 to 1,215,326 services). In 2024, about 458 clinicians billed Medicare for J9349 for 209 beneficiaries; Texas, Florida, California accounted for 76% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1D — Chemotherapy |
| Added | 2021-04-01 |
| Last action effective | 2021-04-01 |
Who bills J9349 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 458 |
| Medicare beneficiaries | 209 |
| States with claims | 6 |
| Share of services in top 3 states (Texas, Florida, California) | 76% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J9349, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 1,481,832 | 275 | $12.72 | $10.16 |
| 2023 | 1,343,047 | 235 | $12.96 | $10.32 |
| 2024 | 1,215,326 | 209 | $13.21 | $10.52 |
States with the most J9349 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Texas | 202,010 | $10.71 |
| Florida | 171,889 | $10.72 |
| California | 165,382 | $10.69 |
| Arizona | 70,900 | $10.71 |
| New York | 50,279 | $10.70 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 900 | Prescribing Information |
| practitioner claims | 900 | Prescribing Information |
What changed for J9349
- 2021-04-01: J9349 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J9349?
J9349 is the HCPCS Level II code for injection, tafasitamab-cxix, 2 mg. Short descriptor: "Inj., tafasitamab-cxix".
How much does Medicare pay for J9349?
In 2024, the average Medicare payment was $10.52 per service (average allowed $13.21).
Does Medicare cover J9349?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J9349 can be billed per day?
900 on outpatient hospital claims; 900 on practitioner claims (NCCI medically unlikely edits).
Related J93 codes
- J9300 — Injection, gemtuzumab ozogamicin, 5 mg
- J9301 — Injection, obinutuzumab, 10 mg
- J9302 — Injection, ofatumumab, 10 mg
- J9303 — Injection, panitumumab, 10 mg
- J9304 — Injection, pemetrexed (pemfexy), 10 mg
- J9305 — Injection, pemetrexed, not otherwise specified, 10 mg
- J9306 — Injection, pertuzumab, 1 mg
- J9307 — Injection, pralatrexate, 1 mg
- J9308 — Injection, ramucirumab, 5 mg
- J9309 — Injection, polatuzumab vedotin-piiq, 1 mg
- J9310 — Injection, rituximab, 100 mg
- J9311 — Injection, rituximab 10 mg and hyaluronidase
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J9349
- Watch J9349 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J9349
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.